関連する実験動画
Updated: Jan 27, 2026

03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
2.0K
薬学的な治療を超えて:心不全の病理生理学的側面を標的とした治療法についての洞察
Camilla Normand1, David M Kaye2, Thomas J Povsic3
1Department of Cardiology, Stavanger University Hospital, Stavanger, Norway; Institute of Internal Medicine, University of Bergen, Bergen, Norway.
Lancet (London, England)
|March 13, 2019
まとめ
心不全の治療における進歩は 特定の病理生理学的メカニズムを標的としています 新しい治療法には,心筋再同期,静脈刺激,心房間シャント,心筋再生のための細胞療法があります.
科学分野:
- 心臓病科
- 生物医学工学
- 再生医療
背景:
- 心不全は,著しい罹病率と死亡率で特徴づけられる一般的な状態です.
- 現在の管理は主に薬学的介入に依存しています.
- 心不全の複雑な病理生理学は ターゲットを絞った治療戦略を必要とします
研究 の 目的:
- 心不全の治療における 最新の進歩を紹介します
- 病理生理学的メカニズムに特化した治療法を強調する.
- 伝統的な薬理学的治療法を超えた革新的なアプローチを探求する.
主な方法:
- 心臓再同期療法と 電気メカニカル不協和症と不律症に対する 埋め込み式心房変圧器
- ニューロ・ユーモラル・モジュレーションのための バロ・リフレックスとヴァーガル・神経刺激
- 心臓の改造を防ぐために
- 直接心筋を標的にし 再生する細胞療法
主要な成果:
- 特定の心不全メカニズムに対処する標的治療の有効性が実証された.
- リズムと電気伝導のための装置ベースの介入の成功.
- 神経刺激と構造的介入の結果が期待できる
- 心筋修復のための細胞ベースのアプローチの潜在的可能性
結論:
- 標的型療法では 心不全の複雑な病理生理学に 取り組む新しい方法が 提供されます
- デバイスベース,神経刺激,構造,再生戦略を組み合わせた多面的なアプローチが有望である.
- これらの進歩は,メカニズム特有の心不全治療への重要な転換を意味します.
関連する概念動画
Pathophysiology of Heart Failure
3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
Heart Failure II: Pathophysiology
855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
Heart Failure VI: Adjunct Therapies
313
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
313
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
611
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
611
Heart Failure I: Introduction
829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
Heart Failure Drugs: Diuretics
935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935

